ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Return
45.88%
This Quarter Return
+24.05%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$59.8M
AUM Growth
+$23.7M
(+65%)
Cap. Flow
+$13.2M
Cap. Flow
% of AUM
22.09%
Top 10 Holdings %
Top 10 Hldgs %
72.36%
Holding
33
New
10
Increased
11
Reduced
3
Closed
8
Top Buys
| 1 |
Gilead Sciences
GILD
|
$4.54M |
| 2 |
Inogen
INGN
|
$4.15M |
| 3 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$3.25M |
| 4 |
Illumina
ILMN
|
$2.58M |
| 5 |
CBIO
Crescent Biopharma, Inc. Common Stock
CBIO
|
$1.71M |
Top Sells
| 1 |
Insmed
INSM
|
$6.35M |
| 2 |
Incyte
INCY
|
$2.01M |
| 3 |
Neurocrine Biosciences
NBIX
|
$1.47M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$1.11M |
| 5 |
DaVita
DVA
|
$1.09M |
Sector Composition
| 1 | Healthcare | 82.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Bio-Rad Laboratories Class A
BIO
$7.83B
| – | – |
-1,745
| Closed | -$405K |
|
27
DURECT Corp
DRRX
$59.3M
| – | – |
-22,882
| Closed | -$111K |
|
|
28
DaVita
DVA
$9.69B
| – | – |
-21,156
| Closed | -$1.09M |
|
29
Equillium
EQ
$62.5M
| – | – |
-60,882
| Closed | -$497K |
|
30
Amicus Therapeutics
FOLD
$2.47B
| – | – |
-97,294
| Closed | -$932K |
|
|
31
Incyte
INCY
$16.7B
| – | – |
-31,588
| Closed | -$2.01M |
|
|
32
Neurocrine Biosciences
NBIX
$13.9B
| – | – |
-20,571
| Closed | -$1.47M |
|
|
KDMN
33
DELISTED
Kadmon Holdings, Inc.
KDMN
| – | – |
-192,637
| Closed | -$401K |
|